Newport News, VA – July 20, 2021 – Today, ivWatch, LLC announced the approval of two more patent grants in Canada and Europe. In addition, the company also received registered trademark approval for SmartTouch®, a miniaturized and disposable sensor for continuous IV monitoring, in the United States. The two new patents bring the company’s patent portfolio to 41, up from 39 earlier in 2021. These patents allow ivWatch to continue to protect its technologies and intellectual properties in strategic markets around the world.
ivWatch is on the cutting-edge of technology when it comes to the company’s biosensors, maintaining its status in the market as the first and only continuous IV site monitoring system.
“We have an excellent team of research engineers at ivWatch that continue to push technology into new realms within the software and biosensor space,” said Gary Warren, President and CEO, ivWatch. “As we continue to grow globally, we remain confident in our path to protect our proprietary intellectual property.”
Canada Patent No. 2867138 covers the geometry of a transcutaneous sensor. ivWatch’s biosensors emit visible, near-infrared light and collect data using electromagnetic radiation. This patent secures the company’s methods of collecting valuable tissue data around an IV insertion site.
Europe Patent No. 3563758 addresses the systems and methods for mitigating the effects of tissue blood volume changes from limb movement. These two patented processes allow the company’s biosensors to aid in the early diagnosis of IV infiltrations or extravasations.
In addition to adding these patents to ivWatch’s ever-growing portfolio, registered trademark approval was granted in the United States for SmartTouch by the U.S. Patent and Trademark Office. The company was also granted trademark approval in Canada for the “IV drip” logo design.
More than 20 trademark applications have been filed in total around the world to protect the company’s intellectual properties. These new patents and trademarks come on the heels of four other international patents that were granted in late 2020 and the FDA clearance of the SmartTouch sensor in July 2020.
About ivWatch, LLC
ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative IV monitoring solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch, Facebook @ivWatchLLC, and LinkedIn @ivWatch-LLC, or visit www.ivWatch.com.
Mobile (757) 633-4688